Rapport Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 |
|---|---|---|---|---|
| Income Statement | ||||
| Research and development | $94.8M | $60.9M | $28.0M | — |
| Operating expenses | $125.1M | $83.1M | $36.2M | — |
| Operating income | -$125.1M | -$83.1M | -$36.2M | — |
| Pretax income | — | -$78.3M | -$34.8M | — |
| Income tax expense | $0 | $0 | $10,000 | — |
| Net income | -$111.5M | -$78.3M | -$34.8M | — |
| Balance Sheet | ||||
| Cash and equivalents | $52.6M | $56.8M | $70.2M | — |
| Current assets | $498.6M | $309.8M | $150.9M | — |
| Total assets | $512.4M | $314.9M | $155.4M | — |
| Current liabilities | $19.0M | $8.8M | $8.8M | — |
| Total liabilities | $27.8M | $9.5M | $14.5M | — |
| Stockholders' equity | $484.7M | $305.4M | -$25.6M | -$10.1M |
| Cash Flow Statement | ||||
| Cash from operations | -$87.5M | -$64.8M | -$27.2M | — |
| Depreciation and amortization | $1.0M | $839,000 | $112,000 | — |
| Stock-based compensation | $18.9M | $10.2M | $3.5M | — |
| Capital expenditure | $616,000 | $2.4M | $1.6M | — |
| Free cash flow | -$88.1M | -$67.2M | -$28.8M | — |
| Share repurchases | $1,000 | — | $4,000 | — |
| Impairments | $0 | $0 | $0 | — |
Shares outstanding 47.8M · Free float 64.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.